123 Main Street, New York, NY 10001
Investor Relations
Co-Diagnostics, Inc. Reports First Quarter 2023 Financial Results
Clinical trials for Co-Dx PCR Home™ platform remain on track;
Solid cash position and grant funding support long-term strategy
SALT LAKE CITY, May 11, 2023 /PRNewswire/ -- Co-Diagnostics, Inc. (NASDAQ: CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today financial results for the quarter ended March 31, 2023.
First Quarter 2023 Financial Results:
- Revenue of $0.6 million, down from $22.7 million during the prior year primarily due to lower global demand for the Logix Smart™ COVID-19 tests
- Gross profit of $0.1 million, representing 16.6% of consolidated revenue
- Operating loss of $10.0 million compared to operating income of $9.8 million a year ago, due to lower revenue and continued investments into research and development for the Co-Dx PCR Home™ Platform
- Net loss of $5.8 million, compared to net income of $11.7 million in the prior year, representing EPS loss of $0.20 per fully diluted share, compared to EPS of $0.34 in 2022
- Adjusted EBITDA loss of $7.2 million
- Repurchased 0.3 million shares of common stock at an average price of $1.56 per share for an aggregate purchase price of approximately $0.5 million
- Cash, cash equivalents, and marketable securities of $75.3 million as of March 31, 2023
Dwight Egan, Co-Diagnostics' Chief Executive Officer, said, "Our financial performance during the quarter reflects the expected decline in COVID-related sales year-over-year. However, we continue to advance our longer-term strategy, most notably with progress in our clinical evaluations for our Co-Dx PCR Home™ platform. We believe that the innovation of this new platform has been validated after recently receiving notification of various grant awards, which we expect will be the subject of future press releases."
Mr. Egan continued, "Looking ahead, we remain focused in our strategy and will continue to leverage our assets and impressive team to deliver innovative and affordable diagnostic testing solutions. To help guide and measure our progress through the remainder of this year, we have established a set of goals we anticipate achieving. We expect completion of clinical evaluations for our Co-Dx PCR Home™ platform and submission to the FDA by the end of this calendar year. We also anticipate clinical trials for our ABC+RSV tests (both for clinical laboratories and on the new platform) to commence during this upcoming flu season."
Conference Call and Webcast
Co-Diagnostics will host a conference call and webcast at 4:30 p.m. EDT today to discuss its financial results with analysts and institutional investors. The conference call and webcast will be available via:
Webcast: ir.codiagnostics.com on the Events & Webcasts page
Conference Call: 844-481-2661 (domestic) or 412-317-0652 (international)
The call will be recorded and later made available on the Company's website: https://codiagnostics.com.
*The Co-Dx PCR Home platform is subject to FDA review and is not currently for sale.
About Co-Diagnostics, Inc.:
Co-Diagnostics, Inc., a Utah corporation, is a molecular diagnostics company that develops, manufactures and markets state-of-the-art diagnostics technologies. The Company's technologies are utilized for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA). The Company also uses its proprietary technology to design specific tests for its Co-Dx PCR Home™ platform and to locate genetic markers for use in applications other than infectious disease.
Non-GAAP Financial Measures:
This press release contains adjusted EBITDA, which is a non-GAAP measure defined as net income excluding depreciation, amortization, income tax (benefit) expense, net interest (income) expense, stock-based compensation, and one-time transaction related costs. The Company believes that adjusted EBITDA provides useful information to management and investors relating to its results of operations. The Company's management uses this non-GAAP measure to compare the Company's performance to that of prior periods for trend analyses, and for budgeting and planning purposes. The Company believes that the use of adjusted EBITDA provides an additional tool for investors to use in evaluating ongoing operating results and trends and in comparing the Company's financial measures with other companies, many of which present similar non-GAAP financial measures to investors, and that it allows for greater transparency with respect to key metrics used by management in its financial and operational decision-making.
Management does not consider the non-GAAP measure in isolation or as an alternative to financial measures determined in accordance with GAAP. The principal limitation of the non-GAAP financial measure is that it excludes significant expenses that are required by GAAP to be recorded in the Company's financial statements. In order to compensate for these limitations, management presents the non-GAAP financial measure together with GAAP results. Non-GAAP measures should be considered in addition to results prepared in accordance with GAAP, but should not be considered a substitute for, or superior to, GAAP results. A reconciliation table of the net income, the most comparable GAAP financial measure to adjusted EBITDA, is included at the end of this release. The Company urges investors to review the reconciliation and not to rely on any single financial measure to evaluate the company's business.
Forward-Looking Statements:
This press release contains forward-looking statements. Forward-looking statements can be identified by words such as "believes," "expects," "estimates," "intends," "may," "plans," "will" and similar expressions, or the negative of these words. Such forward-looking statements are based on facts and conditions as they exist at the time such statements are made and predictions as to future facts and conditions. Forward-looking statements in this release include statements regarding (i) completion of development and FDA submission for approval of the Co-Dx PCR Home platform, (ii) completion of clinical evaluations for our Co-Dx PCR Home platform, and (iii) clinical trials for our ABC+RSV tests to commence during this upcoming flu season. Forward-looking statements are subject to inherent uncertainties, risks and changes in circumstances. Actual results may differ materially from those contemplated or anticipated by such forward-looking statements. Readers of this press release are cautioned not to place undue reliance on any forward-looking statements. There can be no assurance that any of the anticipated results will occur on a timely basis or at all due to certain risks and uncertainties, a discussion of which can be found in our Risk Factors disclosure in our Annual Report on Form 10-K, filed with the Securities and Exchange Commission (SEC) on March 16, 2023, and in our other filings with the SEC. The Company does not undertake any obligation to update any forward-looking statement relating to matters discussed in this press release, except as may be required by applicable securities laws.
CO-DIAGNOSTICS, INC. AND SUBSIDIARIES CONSOLIDATED BALANCE SHEETS (Unaudited) | ||||||||
March 31, 2023 | December 31, 2022 | |||||||
Assets | ||||||||
Current assets | ||||||||
Cash and cash equivalents | $ | 6,359,380 | $ | 22,973,803 | ||||
Marketable investment securities | 68,920,535 | 58,289,066 | ||||||
Accounts receivable, net | 2,702,196 | 3,453,723 | ||||||
Inventory, net | 5,294,653 | 5,310,473 | ||||||
Income taxes receivable | 1,695,480 | 1,870,419 | ||||||
Prepaid expenses and other current assets | 913,175 | 761,187 | ||||||
Note receivable | 37,500 | 75,000 | ||||||
Total current assets | 85,922,919 | 92,733,671 | ||||||
Property and equipment, net | 2,510,083 | 2,539,483 | ||||||
Operating lease right-of-use asset | 952,176 | 372,115 | ||||||
Intangible assets, net | 26,661,667 | 26,768,333 | ||||||
Investment in joint venture | 950,001 | 672,679 | ||||||
Total assets | $ | 116,996,846 | $ | 123,086,281 | ||||
Liabilities and stockholders' equity | ||||||||
Current liabilities | ||||||||
Accounts payable | $ | 829,819 | $ | 952,296 | ||||
Accrued expenses, current | 1,492,611 | 934,447 | ||||||
Operating lease liability, current | 277,290 | 297,209 | ||||||
Contingent consideration liabilities, current | 992,229 | 1,689,471 | ||||||
Deferred revenue | 18,120 | - | ||||||
Total current liabilities | 3,610,069 | 3,873,423 | ||||||
Long-term liabilities | ||||||||
Income taxes payable | 1,193,080 | 1,181,284 | ||||||
Deferred tax liability | 203,335 | 2,417,987 | ||||||
Operating lease liability | 658,137 | 50,708 | ||||||
Contingent consideration liabilities | 702,455 | 1,042,885 | ||||||
Total long-term liabilities | 2,757,007 | 4,692,864 | ||||||
Total liabilities | 6,367,076 | 8,566,287 | ||||||
Commitments and contingencies (Note 10) | ||||||||
Stockholders' equity | ||||||||
Convertible preferred stock, $0.001 par value; 5,000,000 shares authorized; 0 shares issued and outstanding as of March 31, 2023 and December 31, 2022, respectively | - | - | ||||||
Common stock, $0.001 par value; 100,000,000 shares authorized; 34,823,015 shares issued and 30,632,345 shares outstanding as of March 31, 2023 and 34,754,265 shares issued and 30,872,607 shares outstanding as of December 31, 2022 | 34,823 | 34,754 | ||||||
Treasury stock, at cost; 4,190,670 and 3,881,658 shares held as of March 31, 2023 and December 31, 2022, respectively | (14,694,062) | (14,211,866) | ||||||
Additional paid-in capital | 90,641,608 | 88,472,935 | ||||||
Accumulated other comprehensive income | 471,761 | 293,140 | ||||||
Accumulated earnings | 34,175,640 | 39,931,031 | ||||||
Total stockholders' equity | 110,629,770 | 114,519,994 | ||||||
Total liabilities and stockholders' equity | $ | 116,996,846 | $ | 123,086,281 | ||||
See accompanying notes to unaudited condensed consolidated financial statements |
CO-DIAGNOSTICS, INC. AND SUBSIDIARIES CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS) (Unaudited) | ||||||||
Three Months Ended March 31, | ||||||||
2023 | 2022 | |||||||
Revenue | $ | 601,957 | $ | 22,699,044 | ||||
Cost of revenue | 502,241 | 3,281,951 | ||||||
Gross profit | 99,716 | 19,417,093 | ||||||
Operating expenses | ||||||||
Sales and marketing | 1,706,331 | 2,652,148 | ||||||
General and administrative | 3,013,965 | 2,922,195 | ||||||
Research and development | 5,014,060 | 3,771,327 | ||||||
Depreciation and amortization | 316,010 | 247,264 | ||||||
Total operating expenses | 10,050,366 | 9,592,934 | ||||||
Income (loss) from operations | (9,950,650) | 9,824,159 | ||||||
Other income | ||||||||
Interest income | 202,372 | 11,393 | ||||||
Realized gain on investments | 418,082 | - | ||||||
(Loss) on disposition of assets | - | (93,421) | ||||||
Gain on remeasurement of acquisition contingencies | 1,037,672 | 3,379,890 | ||||||
Gain (loss) on equity method investment in joint venture | 277,322 | (21,339) | ||||||
Total other income | 1,935,448 | 3,276,523 | ||||||
Income (loss) before income taxes | (8,015,202) | 13,100,682 | ||||||
Income tax provision (benefit) | (2,259,811) | 1,386,087 | ||||||
Net income (loss) | $ | (5,755,391) | $ | 11,714,595 | ||||
Other comprehensive income | ||||||||
Change in net unrealized gains on marketable securities, net of tax | $ | 178,621 | $ | - | ||||
Total other comprehensive income | $ | 178,621 | $ | - | ||||
Comprehensive income (loss) | $ | (5,576,770) | $ | 11,714,595 | ||||
Earnings per common share: | ||||||||
Basic | $ | (0.20) | $ | 0.35 | ||||
Diluted | $ | (0.20) | $ | 0.34 | ||||
Weighted average shares outstanding: | ||||||||
Basic | 29,483,540 | 33,935,570 | ||||||
Diluted | 29,483,540 | 34,711,476 | ||||||
See accompanying notes to unaudited condensed consolidated financial statements |
CO-DIAGNOSTICS, INC. AND SUBSIDIARIES GAAP AND NON-GAAP MEASURES (Unaudited) | ||||||||
Reconciliation of net income to adjusted EBITDA: | ||||||||
Three Months Ended March 31, | ||||||||
2023 | 2022 | |||||||
Net income (loss) | $ | (5,755,391) | $ | 11,714,595 | ||||
Interest income | (202,372) | (11,393) | ||||||
Realized gain on investments | (418,082) | - | ||||||
Depreciation and amortization | 316,010 | 247,264 | ||||||
Transaction costs | - | 133 | ||||||
Change in fair value of contingent consideration | (1,037,672) | - | ||||||
Stock-based compensation expense | 2,168,742 | 1,375,097 | ||||||
Income tax provision | (2,259,811) | 1,386,087 | ||||||
Adjusted EBITDA | $ | (7,188,576) | $ | 14,711,783 | ||||
SOURCE Co-Diagnostics
For further information: Andrew Benson, Head of Investor Relations, +1 801-438-1036, investors@codiagnostics.com; Investor Relations Contact: William Stack, Lambert & Co., +1 616-258-5804, wstack@lambert.com
